CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity

HETH R. TURNQUIST1,2,4, XUEDE LIN1, ABDELKADER E. ASHOUR1,3, MICHAEL A. HOLLINGSWORTH1,3, RAKESH K. SINGH2, JAMES E. TALMADGE2 and JOYCE C. SOLHEIM1,3

1Eppley Institute for Research in Cancer and Allied Diseases; Departments of 2Pathology and Microbiology, 3Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA

Received October 20, 2006; Accepted December 1, 2006

Abstract. Chemokines are vital messengers that regulate immune cell activity. The chemokine CCL21 is normally expressed in secondary lymphoid organs and acts as a chemo-attractant for several populations of immune cells. Herein, we report that intratumoral CCL21 administration recruited significant numbers of immune cells into murine pancreatic tumors and inhibited tumor growth. Detailed flow cytometric and confocal analysis of CCL21-treated tumor cell isolates revealed increased lymphoid-related dendritic cells (IDC) and myeloid DC (mDC), naïve and mature T cells, natural killer (NK) cells, and NKT cells infiltrating the tumor mass. Furthermore, CCL21 intratumoral treatments resulted in significant tumor growth inhibition in wild-type (WT) C57BL/6 mice, but no therapeutic benefit was observed in C57BL/6 RAG2 -/- Pfp-/- mice, suggesting that the growth inhibition observed was immunologically mediated. CCL21 intratumoral injections generated immune responses that were tumor-specific and that could be transferred to naïve animals via splenocytes. In addition, intratumoral injection of CCL21 into pancreatic tumors reduced the growth of distant tumors as well as treated tumors. Thus, these data demonstrate in a pancreatic tumor model that intratumoral administration of CCL21 can cause significant immune cell infiltration of the tumor mass, delay growth of treated tumors, and generate a tumor-specific cellular immune response.

Introduction

CCL21 acts in the secondary lymphoid organs as a chemo-attractant (1). The CCL21R, CCR7, is found on diverse populations of T cells and maturing mDC and IDC, and has been detected on NK and NKT cells (2-9). CCR7 expression allows migration along CCL21 gradients formed on the extracellular matrix of endothelial cells of the lymphoid organs, which constitutively secrete CCL21 (10,11). Besides its role in chemotaxis, CCL21 can induce endocytosis by mature DC, which may facilitate DC cross-presentation of antigen (12). In addition, CCL21, acting on vascular endothelial cells via binding to an alternative chemokine receptor, CXCR3, has been reported to have angiostatic effects in mice (13,14).

The ability of CCL21 to act as a chemoattractant for DC and T cells has recently led to evaluations of its therapeutic efficacy. Transfection of the CCL21 cDNA into a colon carcinoma cell line reduced tumor growth in both immuno-competent and nude mice, through immune and angiostatic mechanisms (14). In murine models of melanoma and mammary cancer, a daily intratumoral injection of recombinant murine CCL21 for three days inhibited tumor growth (15). Intratumoral CCL21 therapy in murine lung cancer models reduced tumor burdens, increased tumor infiltration by T cells and DC, and elevated tumor levels of interferon-γ, CXCL10, CXCL9, granulocyte macrophage-colony stimulating factor, and interleukin (IL)-12 (16,19). In conjunction, CCL21 treatment of murine lung tumors decreased the levels of prostaglandin E2, vascular endothelial growth factor, IL-10, and transforming growth factor-β in the injected tumors (16,17). Intratumoral, intranodal, and s.c. administration of DC modified to express CCL21 has also demonstrated promise in mouse models of cancer (15,19,20).

Pancreatic cancer arises asymptomatically and is often diagnosed late in tumor development. Since current therapies do not prolong survival, the median lifespan after diagnosis is <6 months (21,22). Recently, pancreatic tumor samples from
patients who had undergone surgical resection revealed a direct correlation between the intratumoral numbers of CD4+ and CD8+ T cells and overall survival (23). Furthermore, samples with infiltrating CD4+ and CD8+ T cells also displayed increased numbers of DC (23). This association has been substantiated by separate clinical findings demonstrating that an increase in the number of DC infiltrating a pancreatic tumor is associated with improved prognosis, and that pancreatic adenocarcinomas typically display a lack of infiltrating DC (24). The recruitment of DC to pancreatic tumors would be expected to improve prognosis by increasing DC phagocytosis of apoptotic and necrotic tumor cells and enhancing the presentation of relevant tumor antigen (25,26). Furthermore, the stimulation of local immune cells by infiltrating mature DC, via cytokine secretion and displayed stimulatory molecules, would also be expected to facilitate anti-tumor responses.

We hypothesized that intratumoral injections of CCL21 could attract immune cells, including DC and T cells, and inhibit tumor growth of established murine pancreatic tumors. In our studies, we found that pancreatic tumors treated with intratumoral CCL21 became infiltrated with significantly increased numbers of CD8+ T cells, NK cells, NKT cells, and both IDC and mDC. T cell and DC infiltration were observed especially in perivascular foci within the treated tumors. Intratumoral treatment with CCL21 inhibited the growth of treated tumors in WT mice, but it was not efficacious in RAG2-/-Pfp-/- mice, suggesting an immunological mechanism underlies CCL21 therapeutic activity in this tumor model. Furthermore, the immune reactivity generated by intratumoral administration of CCL21 was effective against distant tumors, could be adoptively transferred, and was tumor-specific. These results support the further investigation of CCL21 as a potential immunotherapy for pancreatic cancer.

Materials and methods

Animals, tumor model, and CCL21. Female C57BL/6 mice, 6-8 weeks of age, were purchased from the National Cancer Institute (Frederick, MD) and female RAG2-/-Pfp-/- mice were obtained from Taconic (Germantown, NY). All mice were 10 weeks of age at the initiation of studies. The animals were housed in pathogen-free conditions and experiments were carried out under an approved institutional animal care and use protocol.

For assessment of CCL21-induced anti-tumor responses, Panc02 cells were thawed from a bank of low passage, parental stock cells and passaged only twice before injection. The cells were cultured in McCoy’s 5A media supplemented with 10% FBS, 10 mM HEPES, 2 mM L-glutamine, penicillin (50 U/ml), and streptomycin (50 μg/ml) in 5% CO2. All culture reagents were purchased from Invitrogen (Grand Island, NY). Recombinant murine CCL21 was obtained from PeproTech (Rocky Hill, NJ), and was delivered in 50 μl sterile PBS with 0.05% normal mouse serum (Jackson Immunoresearch Laboratories, Inc., West Grove, PA). Control PBS injections also included 0.05% normal mouse serum.

Tumor inhibition. To compare the response of WT and RAG2-/-Pfp-/- mice to CCL21 tumor therapy, C57BL/6 or RAG2-/-Pfp-/- mice were first given subcutaneous (s.c.) injections of 1x10^6 Panc02 cells dorsally between the scapulae. Once tumors were palpable (mean 12 mm^3, day 20), the mice were randomized into treatment cohorts (8 mice/group). At the time of treatment, the tumors were not significantly different in size between treatment and control groups (p=0.78 for the two groups of C57BL/6 mice and p=0.73 for the two groups of RAG2-/-Pfp-/- mice). Treatments of either 1 μg CCL21 or PBS were delivered intratumorally on days 1, 2, and 3, followed by 4 days without treatment, and again for 3 consecutive days (on days 8, 9, and 10). Tumors were measured with calipers in two perpendicular directions twice per week.

To analyze effects of CCL21 intratumoral treatment on growth of untreated tumors, Panc02 tumor cells were injected subcutaneously into C57BL/6 mice (n=8-10/group) on both flanks, and once tumors were palpable (at approximately day 20) right flank tumors (mean volume 18.5 mm^3) were injected daily with CCL21 or PBS for 2 cycles of 3 daily treatments, 4 days apart. The left flank tumors (mean volume 6.0 mm^3) of both groups were not treated. The change in mean tumor volume over time for treated and untreated tumors was monitored.

Winn assay. Groups of C57BL/6 mice (n=5-14) were injected s.c. above the scapulae with 1x10^6 Panc02 cells. Once these tumors were palpable, mice were randomized into groups that did not differ significantly in tumor volume and treated as described previously (PBS n=6-10; CCL21 n=10-14). On day 11 or 13 post-treatment initiation, the animals were sacrificed. Splenic leukocytes obtained from PBS- or CCL21-treated mice were pooled, mixed with Panc02 or 3LL cells, and injected s.c. above the scapulae of naïve C57BL/6 mice (5x10^7 splenocytes:5x10^7 tumor cells per mouse). Time to tumor development and tumor growth rate were recorded.

Histological and immunohistochemical analysis. C57BL/6 mice were given s.c. tumors above the scapulae as described above. Randomized cohorts of mice (n=2-4) with tumors not significantly different in size received intratumoral injections of CCL21 or PBS. On the fifth day following the last treatment (day 15), animals were sacrificed, and tumors and marginal tissue were resected. The tumors were bisected at the midline, half was embedded in Tissue Freezing Media (Triangle Biomedical Sciences, Durham, NC) and flash frozen in liquid nitrogen, and the opposing half was fixed in 10% buffered formalin, paraffin-embedded, sectioned, and stained with hematoxylin and eosin. Frozen tumor samples were cryosectioned and fixed in ice cold 1:1 acetone:methanol. Non-specific binding was blocked with 10% normal goat serum (Vector Laboratories, Burlingame, CA) and then the sections were incubated with antibodies for 2 h at room temperature. Antibodies were used that recognize CD3 (Rabbit IgG; Dako-Cytomation, Carpinteria, CA) and CD205 (NLDC-145, Rat IgG2a; BD PharMingen). Following the incubation, sections were overlaid with species-specific secondary antibody and incubated at room temperature for 1 h. The antibodies were cross-linked with 2% paraformaldehyde, the slides were coverslipped, and fluorescence images of the sections were obtained using a Zeiss Confocal Microscope LSM410.
Tumor harvest and flow cytometric analysis of infiltrating cells. Panc02 tumors were treated as described above with CCL21 or PBS (n=2-4 mice per treatment cohort). Twenty-four hours after the last treatment (day 11), the tumors were resected and non-necrotic tumor tissue was minced. Following treatment with collagenase (200 U/ml; Sigma-Aldrich, St. Louis, MO) and deoxyribonuclease I (270 Kl/ml; Sigma-Aldrich) at 37°C for 1 h, the mononuclear cells were isolated with lympho-line®M (Cedarlane, Hornby, Ontario), and stained for flow cytometric analysis. The antibodies used were labeled with fluorescein isothiocyanate (FITC), biotin, or phycoerythrin (PE) (BD PharMingen). Biotinylated antibodies were revealed with allophycocyanin (APC)-streptavidin (Molecular Probes, Eugene, OR). The following antibodies were utilized in the flow cytometric analysis (clone designations and isotypes are indicated): CD3 (145-2C11, Armenian hamster IgG1,κ), CD4 (H129.19, Rat IgG2a,κ), CD8 (53-6.7, Rat IgG2a,κ), CD25 (PC61, Rat IgG1,κ), CD11b (M1/70, Rat IgG1,κ), B220 (RA3-6B2, Rat IgG2a,κ), CD25 (PC61, Rat IgG1,λ), and Gr-1 (RB6-8C5, Rat IgG2a,x). Data on the stained samples were acquired with a FACSCalibur flow cytometer (BD ImmunoCytometry Systems, San Jose, CA), and gating on forward and side scatter was performed before analysis of antibody staining. Per sample, 30,000-100,000 events were collected, and the data were analyzed with Attractors, CellQuest (BD ImmunoCytometry Systems), or FCSPress 1.4 (Ray Hicks, Cambridge, UK).

**Statistical analysis.** Statistical differences between treatment groups in the percentage of animals remaining tumor-free were calculated using the log-rank test in the GraphPad Prism 2.0C Software package (GraphPad Software, Inc., San Diego, CA). Determination of significant differences in tumor growth over time was performed with the JMP IN 4.04 Statistical Package (SAS Institute Inc., Cary, NC) utilizing repeated measure multivariate analysis of variance (MANOVA). The Student’s t-test in JMP IN 4.04 was used to determine statistical significance (p<0.05) for differences in tumor volume at independent time points or in the number of tumor-infiltrating immune cells with separate phenotypes.

**Results**

CCL21 injection slowed the growth of treated tumors. To determine whether CCL21 has potential therapeutic efficacy against pancreatic cancer, we examined the effect of intratumoral CCL21 injections against tumors arising from s.c. injected Panc02 cells. Panc02 is a C57BL/6-derived pancreatic cancer cell line (27). Following the development of tumors (12 mm³ in mean volume) in WT C57BL/6 mice, daily intratumoral injections of CCL21 or PBS for 3 days in 2 cycles, spaced 4 days apart, were initiated. As shown in Fig. 1A, intratumoral CCL21 treatment significantly inhibited tumor growth in WT C57BL/6 mice, beginning on day 4 following the initial treatment. Maximal inhibition occurred on days 11-14, at which time CCL21-treated tumors averaged 85% less volume than tumors treated with PBS for the same time period. CCL21 toxicity was not likely to be responsible for the decreased tumor growth, as we found that CCL21 did not reduce the growth rate of Panc02 in vitro at 10 μg/ml, which is ~1000-fold greater than the concentration of CCL21 in the injected mouse tumors (data not shown).

To investigate the mechanism for the observed CCL21 therapeutic activity, CCL21 or PBS was also injected into Panc02 tumors in C57BL/6 RAG2<sup>-/-</sup>Pfp<sup>-/-</sup> mice (deficient in functional T, B, and NK cells), just as described above for WT C57BL/6 mice. On day 14 after the initiation of therapy, the volumes of CCL21-treated tumors from RAG2<sup>-/-</sup>Pfp<sup>-/-</sup> mice were very similar to those of tumors from C57BL/6 and RAG2<sup>-/-</sup>Pfp<sup>-/-</sup>-treated mice (Fig. 1B). These results suggest that the tumor growth inhibition that was observed in C57BL/6 mice was immunologically mediated.

CCL21 reduced the rate of distant as well as local tumor growth in a pancreatic tumor model. To analyze distant effects of CCL21 intratumoral treatment, we injected Panc02 tumor cells into mice at two separate sites, and treated one of the resultant tumors. Specifically, subcutaneous tumors were
Figure 3. Systemic anti-tumor responses generated by CCL21 treatment of Panc02 tumors were tumor-specific and transferable via splenocytes to naïve animals. Upon development of palpable s.c. Panc02 tumors in mice, intratumoral CCL21 (n=10-14) or PBS (n=6-10) was injected on days 1, 2, 3, 8, 9, and 10. On day 13, the animals were sacrificed and splenocytes were isolated, pooled, mixed with either Panc02 or 3LL tumor cells, and injected s.c. into naïve C57BL/6 females (n=4-10; 5x10^5 splenocytes: 5x10^5 tumor cells). (A) Change in CCL21- or PBS-treated tumor volumes in animals from which splenocytes were derived. (B) Comparison of tumor growth in Panc02 or 3LL tumor cells (Panc02 or 3LL) mixed with splenocytes from PBS- or CCL21-treated animals. (C) Comparison of the percentage of animals remaining tumor-free following injection with mixed Panc02 tumor cells and splenocytes from CCL21- or PBS-treated animals. The data are representative of one of the two independent experiments.

first established in both flanks of C57BL/6 mice by injection of Panc02 cells (2x10^6 cells in the right flank and 1x10^6 cells in the left flank). After development of the tumors, the right flank tumors (mean volume 18.5 mm^3) were injected daily with CCL21 or PBS for 2 cycles of 3 daily treatments, given 4 days apart. The left flank tumors (mean volume 6.0 mm^3) of both groups received no injections. Fig. 2 depicts the change in mean tumor volume over time for treated (panel A) and untreated (panel B) tumors. Intratumoral CCL21 injection significantly inhibited the growth of tumors in C57BL/6 mice (p=0.0387 through day 18, with 2.5-5.0-fold less tumor volume through day 18) (Fig. 2A). Moreover, tumor inhibition was not limited to the treated tumor, but the growth of the second, non-injected tumor was also significantly slowed (p=0.05 through day 14) (Fig. 2B). For mice that had received CCL21 injections in the right flank tumors, a 14-fold growth rate reduction was observed for the untreated left flank tumors through day 18. These data suggest that CCL21 treatment initiates immune responses capable of acting both locally against the treated primary pancreatic tumor and systemically against a spatially distant tumor.

CCL21 effects were tumor-specific and transferable to naïve animals. To further examine whether the observed delay in Panc02 tumor growth following intratumoral CCL21 injection was accompanied by immune responses that were systemic and tumor-specific, splenocytes from tumor-bearing mice that had been treated intratumorally with CCL21 or PBS were utilized in Winn assays (28). Tumor volumes of animals treated with intratumoral CCL21 or PBS were monitored over time (Fig. 3A), and then the mice were sacrificed and total splenocytes were isolated from each group. When splenocytes were injected into C57BL/6 mice along with Panc02 or syngeneic 3LL tumor cells (at 100:1 splenocytes:tumor cells), the splenocytes from CCL21-treated animals, but not PBS-treated animals, significantly inhibited Panc02 (but not 3LL) tumor growth (Fig. 3B) and delayed tumor onset (Fig. 3C). Thus, these findings demonstrate that a specific, systemic immune response to Panc02 tumors developed following CCL21 intratumoral treatment.

CCL21 injection increased leukocyte infiltration. Hematoxylin and eosin-stained tumor sections from corresponding areas of CCL21- or PBS-treated tumors were examined microscopically to determine the effect of injections of CCL21 on inflammatory cell infiltration. Fifteen days following the initiation of CCL21 or control PBS treatments of matched tumors, the treated tumors and marginal tissues were resected. Sections from a medial plane at the maximal tumor circumference revealed that the PBS-treated tumors (Fig. 4A) had uniform fields of anaplastic tumor cells, infrequently infiltrated with individual inflammatory cells. In contrast to PBS-treated tumors, corresponding regions of CCL21-treated tumors (Fig. 4B) had increased overall inflammatory cell infiltrate and foci of leukocytes around tumor vasculature. Visualization of the vasculature by immunohistochemical staining revealed that the CCL21-treated tumors had a greatly reduced vascular density compared to PBS-treated controls (data not shown), which could be related to anti-angiogenic effects or simply to the reduced development of the CCL21-treated tumors.

Phenotype of the tumor infiltrate induced by intratumoral CCL21 injection. To identify tumor-infiltrating leukocytes, we performed immunofluorescent (IF) and confocal microscopy on cryosections from PBS- and CCL21-treated tumors, using antibodies recognizing murine T cells, NK cells, and DC. PBS-treated tumor sections at day 15 post-treatment initiation had few infiltrating CD3^+ T cells (Fig. 5A). In contrast, CCL21-treated tumor sections had increased numbers of CD3^+ cells spread diffusely throughout the entire section, and the lymphoid-like foci were highly enriched for T cells (Fig. 5B).

By staining PBS-treated tumor sections with antibodies for DC markers, including CD205 (a protein expressed at high levels on murine DC, especially lDC) (29), we found very few infiltrating DC in the PBS-treated tumor sections (Fig. 5C). Similar results for PBS-treated tumors were obtained with antibodies against CD11c and MHC class II (data not shown). In the CCL21-treated tumor sections, more DC were detected in areas of immune cell aggregation co-localized with CD3^+ T cells and NK cells (Fig. 5D and E). Furthermore, staining CCL21-treated tumor samples with antibodies specific for both CD3^+ T cells and MHC class II^+ cells (presumably mostly DC) and analyzing the samples by confocal microscopy revealed some co-localization of T cells with MHC class II^+ cells (Fig. 5F and G).
Figure 4. Panc02 tumors treated intratumorally with CCL21 exhibited an increased number of infiltrating leukocytes. Photomicrographs (x400) show representative areas of tumor sections taken from a medial plane through the maximum tumor circumference. Hematoxylin and eosin staining of these sections from established s.c. dorsal tumors treated with (A) PBS or (B) CCL21 (1 μg) on days 1, 2, 3, 8, 9, and 10 and resected 5 days after the last treatment.

Figure 5. CCL21-treated tumors contained large numbers of co-localized infiltrating T cells, DC, and NK cells. Cryosections of s.c. Panc02 tumors treated with CCL21 or PBS were immunostained using antibodies recognizing the pan T cell marker CD3 (red; A-G), several surface molecules found on DC: CD205 (green; C and D), CD11c (blue; E), or MHC class II (green; F and G), and the NK cell marker Ly-49G2 (green; E) and were examined by confocal microscopy. (F and G) Co-localization of CD3+ cells and MHC class II+ cells is indicated by overlapping color (yellow). (G) Digital magnification (x1200) of an area containing CD3+ cells and MHC class II+ cells from (F) is presented in the upper right corner inset.
Enumeration of tumor-infiltrating leukocytes following CCL21 treatment. Panc02 tumors were dissociated 24 h after the final treatment, and evaluation of phenotypes of infiltrating, non-parenchymal cells by 4-color flow cytometry revealed that CD3+ lymphocytes, but not B220+ B lymphocytes, were significantly increased in number (16-fold) after CCL21 treatment (Fig. 6A). In addition, both NKT cells (NK1.1+CD3+) and NK cells (NK1.1+CD3-) were significantly more numerous in the tumors following CCL21 treatment (Fig. 6B).

The increase in CD3+ cell levels included a significant (26-fold) enhancement in CD3+CD8+ cell numbers following CCL21 injection, but the difference between CCL21 and PBS treatment group CD3+CD4+ cell numbers was not significant (Fig. 6C). CD62L has been described as a surface marker displayed on naïve T cells and lost upon their activation (30). Furthermore, expression of CD62L has been shown to correlate with the presence of CCR7 on both CD4+ and CD8+ T cells, and has previously been used to divide memory T cells into subsets consisting of central memory cells (CD62Lhigh) and effector memory cells (CD62Llow) (6,31). A subset of T cells that was CD3+CD8+CD62L+ (presumably naïve or central memory T cells) was significantly increased in the CCL21-treated tumors (Fig. 6C). However, the great majority of T cells in CCL21-treated tumors expressed low levels of CD62L (Fig. 6C), characteristic of activated T cells. PBS-treated tumors had only rare CD8+ or CD4+ cells positive for CD62L, as well as significantly fewer CD62L- cells than their CCL21 counterparts (Fig. 6C). Thus, CCL21 treatment increased intratumoral infiltration by T cells, particularly those with an activated or mature phenotype.

The expression of IL-2R (CD25) on both CD8+ and CD4+ T cells is indicative of T cell activation, but CD4 and CD25...
DC infiltration of tumors following intratumoral CCL21 treatment. DC subtypes have been proposed to possess intrinsic differences in their ability to polarize CD4+ Th cell responses (35,36), and thus potentially to influence anti-tumor responses. In mice, the mDC subset (CD11c<sup>hi</sup>CD11b<sup>hi</sup>CD8<sup>-</sup>) is associated with IL-12 secretion, and thus with skewing immune responses toward Th2 cell responses (37-39); however, antigen concentration and maturation signals influence the ability of these DC to polarize responses (40). We found that the number of intratumoral mDC was significantly increased after treatment with CCL21, compared with PBS (Fig. 7A). IL-12 secretion, which augments T and NK cell activity, is thought to be a characteristic of murine IDC (CD11c<sup>hi</sup>CD11b<sup>-</sup>CD8<sup>-</sup>) (41,42). In addition, IDC are also known to cross-prime effectively (43). LDC were found in very low numbers in tumors from PBS-treated animals, but were significantly higher in CCL21-treated tumors (Fig. 7B). A third class of DC, the plasmacytoid DC (pDC) subset (defined in mice by CD11c<sup>-</sup>CD11b<sup>B220<sup>+</sup></sup> expression), may suppress anti-tumor T cell responses (44). The numbers of pDC were very low in both PBS- and CCL21-treated tumors (<10 cells/mm<sup>3</sup>) and were unaltered by CCL21 tumor treatment (Fig. 7B).

Discussion

Our results showing that intratumoral CCL21 injection can slow pancreatic tumor growth extend prior studies of CCL21 treatment for murine models of melanoma, breast cancer, and lung cancer (15-18). Our findings also demonstrate that intratumoral CCL21 injection facilitates systemic immune responses that are cell-mediated and tumor-specific. Thus, CCL21 therapy may be of benefit against metastatic disease, if delivered at the primary pancreatic tumor site as a neoadjuvant treatment (i.e., prior to surgical resection of tumor), or if injected into inoperably large tumors.

We found that CCL21-treated tumors (relative to PBS-treated controls) exhibited increased numbers of DC and T cells spread throughout the tumor, as well as clustered together. DC and T cells were especially prevalent in CCL21-treated tumors in areas of vascularization, although overall tumor vascularization in these tumors was reduced (perhaps because of angiostatic effects and/or limited tumor size). The DC infiltrating the tumor following CCL21 injection may facilitate T cell anti-tumor responses through extranodal T cell stimulation (20), as well as by presentation of relevant tumor antigen following migration to regional LN (26). Within the leukocytic aggregates in CCL21-treated tumors, CD11c<sup>+</sup> DC cells were also found co-localized with NK cells. Our data found both IDC and, to a greater extent, mDC were introduced in significant numbers to the tumor microenvironment following CCL21 injection. Past studies have shown murine IDC to be a DC subset that is highly effective at IL-12 and interferon-γ secretion, and are thus expected to be beneficial for efficient local anti-tumor responses (37,45). However, the recent demonstrated ability of mDC to polarize Th1 after appropriate activation via specific Toll-like receptors and high antigen levels (40) suggests that targeting of intratumoral mDC with specific Toll-like receptor ligands following CCL21 injection may be an especially effective immunotherapeutic approach.

The majority of CD8<sup>+</sup> cells found within treated tumors on day 11 post-treatment initiation displayed an activated/mature phenotype, in that they lacked the expression of CD62L (2,30). However, significant tumor growth inhibition started as early as day 4 post-start of therapy, allowing little time for DC priming of a de novo anti-tumor response. This rapid onset of inhibition suggests that CCL21 recruitment of CD8<sup>+</sup> central memory cells, which express CCR7 and are capable of rapid activation upon detection of antigen (31), may be a significant contributor to early CCL21-induced anti-tumor responses.

Also in the present study, we found both NK and NKT cells infiltrated the Panc02 tumor in significantly increased numbers. NK and NKT cells have been observed to undergo chemotaxis in response to CCL21, especially the CD56<sup>dim</sup>CD16<sup>-</sup> population in humans (4,46). A previous antibody depletion
study suggested that NK cells, as well as T cells, play a role in CCL21-facilitated immunological responses (14). However, to our knowledge, our study is the first to identify NK and NKT cells infiltrating the CCL21-treated tumor mass. The inability of injected CCL21 to reduce tumor growth in RAG2-/-Pp^e mice suggests that direct angiostatic effects, if any, were insufficient to have therapeutic impact. Previous studies suggesting a direct angiostatic mechanism for CCL21 (14,47) were distinct from our study in that they used mouse models (SCID and nu/nu) that, although lacking B cells and T cells, still possess fully functional NK cells. Thus, NK cells should be considered as a potentially critical contributor to the mechanism underlying CCL21’s ability to slow tumor growth.

In conclusion, several of our findings support the development of CCL21 as a treatment for pancreatic cancer that acts through in vivo manipulation of immune cell populations. CCL21 was demonstrated to recruit immune cells known to be contributory to anti-tumor responses (DC, T cells, NK cells, and NKT cells) into the tumor. Our observations, coupled with previous data indicating that the level of T cell and DC infiltration is predictive of the duration of survival for pancreatic cancer patients (50), suggest that CCL21 may be of potential value in the neoadjuvant setting and/or for the treatment of non-resectable primary pancreatic tumors and metastases.

Acknowledgements

This study was funded by an LB595/Cattlemen’s Grant (J.C.S.), the NRI Molecular Therapeutics Program (J.E.T., J.C.S., R.K.S. and M.A.H.), and NIH Grant P50 CA72712 (M.A.H. and J.C.S.). H.R.T. received support from the NIH Training Grant T32 CA09476, and H.R.T. and A.E.A. were supported by UNMC Graduate and Presidential Fellowships and by DOD Breast Cancer Research Program Fellowships. Assistance was provided by the UNMC Animal Facility, Cell Analysis Facility, and Confocal Laser Scanning Microscope Core Facility. We thank M. McLhaney, M. Varney, and E. Benner for technical advice.

References
